Table 2 Baseline patient demographic and disease characteristics (FAS)
gBRCAm status | |||
|---|---|---|---|
Positive (N = 33) | Negative (N = 308) | FAS (N = 341) | |
Age at enrollment (years) | |||
n | 33 | 308 | 341 |
Median (range) | 47.0 (25–71) | 56.5 (29–89) | 56.0 (25–89) |
Race, n (%) | |||
n | 28 | 267 | 295 |
White | 22 (78.6) | 201 (75.3) | 223 (75.6) |
Black or African American | 0 | 4 (1.5) | 4 (1.4) |
Asian | 6 (21.4) | 60 (22.5) | 66 (22.4) |
Native Hawaiian or Other Pacific Islander | 0 | 1 (0.4) | 1 (0.3) |
Other | 0 | 1 (0.4) | 1 (0.3) |
Age at initial breast cancer diagnosis (years) | |||
n | 31 | 307 | 338 |
Median (range) | 40.0 (24–71) | 52.0 (24–86) | 50.0 (24–86) |
Family history of breast and/or ovarian cancer, n (%) | |||
n | 33 | 307 | 340 |
Yes | 15 (45.5) | 51 (16.6) | 66 (19.4) |
No | 18 (54.5) | 256 (83.4) | 274 (80.6) |
Time since initial breast cancer diagnosis to enrollment (months) | |||
n | 31 | 307 | 338 |
Median (interquartile range) | 28.1 (13.4–73.0) | 29.9 (6.3–78.2) | 29.8 (7.2–76.8) |
Sites of metastatic disease, n (%) | |||
n | 33 | 308 | 341 |
Bone and locomotor | 13 (39.4) | 162 (52.6) | 175 (51.3) |
Lymph nodes | 15 (45.5) | 134 (43.5) | 149 (43.7) |
Respiratory | 10 (30.3) | 86 (27.9) | 96 (28.2) |
Liver | 8 (24.2) | 69 (22.4) | 77 (22.6) |
Other metastatic sites | 23 (69.7) | 194 (63.0) | 217 (63.6) |
HR status at most recent assessment, n (%) | |||
n | 31 | 303 | 334 |
Positive | 20 (64.5) | 195 (64.4) | 215 (64.4) |
AJCC stage at initial breast cancer diagnosis, n (%) | |||
n | 33 | 303 | 336 |
0 | 1 (3.0) | 8 (2.6) | 9 (2.7) |
Stage I (I, A, B, C) | 3 (9.1) | 28 (9.2) | 31 (9.2) |
Stage II (II, A, B, C) | 13 (39.4) | 104 (34.3) | 117 (34.8) |
Stage III (III, A, B, C) | 8 (24.2) | 80 (26.4) | 88 (26.2) |
Stage IV (IV, A, B, C) | 8 (24.2) | 83 (27.4) | 91 (27.1) |
Nodal status at original diagnosis, n (%) | |||
n | 33 | 307 | 340 |
N0 | 12 (36.4) | 74 (24.1) | 86 (25.3) |
N1 | 8 (24.2) | 106 (34.5) | 114 (33.5) |
N2 | 7 (21.2) | 54 (17.5) | 61 (17.9) |
N3 | 5 (15.2) | 38 (12.4) | 43 (12.6) |
pN0 | 0 | 4 (1.3) | 4 (1.2) |
NX | 1 (3.0) | 29 (9.4) | 30 (8.8) |
N1a | 0 | 2 (0.7) | 2 (0.6) |
Tumor grade at original diagnosis, n (%) | |||
n | 33 | 303 | 336 |
X (undetermined) | 3 (9.1) | 65 (21.5) | 68 (20.2) |
1 (well differentiated) | 2 (6.1) | 22 (7.3) | 24 (7.1) |
2 (moderately differentiated) | 10 (30.3) | 101 (33.3) | 111 (33.0) |
3 (poorly differentiated) | 15 (45.5) | 103 (34.0) | 118 (35.1) |
4 (undifferentiated) | 0 | 3 (1.0) | 3 (0.9) |
High grade* | 3 (9.1) | 9 (3.0) | 12 (3.6) |
Non-chemotherapy treatment prior to metastatic disease, n (%)† | |||
n | 33 | 305 | 338 |
Tamoxifen | 7 (21.2) | 74 (24.3) | 81 (24.0) |
Letrozole | 3 (9.1) | 37 (12.1) | 40 (11.8) |
Anastrozole | 2 (6.1) | 35 (11.5) | 37 (10.9) |
Exemestane | 1 (3.0) | 3 (1.0) | 4 (1.2) |
Fulvestrant | 0 | 8 (2.6) | 8 (2.4) |
Everolimus | 1 (3.0) | 0 | 1 (0.3) |
Other | 1 (3.0) | 11 (3.6) | 12 (3.6) |